Osman Kibar
Osman Kibar is the founder and CEO of biotech firm Samumed.
Samumed said it raised $438 million in August 2018 to further its work developing drugs to reverse aging, claiming a valuation of $12.4 billion.
The names of investors in the round were not disclosed.
While getting a Ph.D. from the University of California, San Diego, he founded two companies, but did not have a management role in either.
He then founded Samumed in 2008 in a Pfizer incubator, but had a falling out with the drug giant; Samumed now operates independent of Pfizer.
